The Covid-19 vaccine, which has recently received a patent and continues its third phase clinical trials in many countries, strengthens hopes.
Zheng Zhongwei, Director of the National Health Commission Science and Technology Development Center and leader of the vaccine research and development team, announced that the vaccine has been in use for more than a month.
Zheng Zhongwei stated that emergency vaccine use is limited to persons within the specified scope, such as medical personnel, epidemic prevention personnel, border inspection personnel. In the next step, to prevent the epidemic during the autumn and winter months, it is planned to expand the scope of emergency use to include core city services such as workers in vegetable markets, transport security personnel and service sector personnel. The goal of choosing this segment is to create an immune barrier between special populations, thus ensuring the functioning of all city life.
220 million doses of vaccine production facility established, 200 million on the way
Huang Libin, director of the Operations Monitoring and Coordination Bureau of the Ministry of Industry and Information Technologies, stated at the press conference held on July 23 that 13 companies across the country have produced new types of coronavirus vaccine. Sinopharm has set up two vaccine production lines in Beijing and Wuhan with an annual production capacity of 220 million doses. Cansino's chairman, Yu Xuefeng, said his company accelerated the construction of the factory and is expected to have an annual production capacity of 200 million doses upon completion.
Regarding the price of the vaccine, Zheng Zhongwei stated that this vaccine is a public health product and pricing may be based on cost. “There is no such thing as companies cannot make a profit, but the profit level should be reasonable. This is a principled attitude ”he said.
Earlier, Liu Jingzhen, chairman of Sinopharm Group, said that the inactivated vaccine is expected to be available by the end of the year, and the price for two doses is less than 1.000 yuan.
Trials are in progress in many countries
At this point, many corona vaccines produced in China entered the final race. On June 23, Sinopharm Zhongsheng's inactivated vaccine became the vaccine that opened up to the world and initiated phase III clinical trials in the United Arab Emirates. Yang Xiaoming, head of Sinopharm Zhongsheng, said the number of people who took part in the trial exceeded 20.000, more than expected, which is good for the safety of the vaccine. Sinopharm has recently signed phase III clinical trial cooperation agreements with Peru, Morocco and Argentina.
Kexing Biotech's inactivated vaccines began phase III clinical trials in Brazil and Indonesia in July. Yin Weidong, Chairman and CEO of Kexing Biotech, stated that vaccination has started at 12 locations across Brazil and all registrations are expected to be completed by the end of September and the observation period will begin.
The adenovirus vector vaccine, jointly developed by the Chinese Academy of Military Sciences and Cansino, released clinical phase II trial data on July 20. The Saudi Arabian Ministry of Health announced its collaboration with the phase III clinical trial on 9 August. 18 healthy volunteers over the age of 5.000 will be selected to conduct experiments in Riyadh, Dammam and Mecca. The Mexican Foreign Ministry announced on August 11 that the third stage clinical trials of the vaccine developed by Cansino and Watson Bio are allowed.
Hibya News Agency